Patents by Inventor Michael Hale Reutershan

Michael Hale Reutershan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PRMT5 inhibitors
    Patent number: 11098059
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: August 24, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, David J. Witter, Michael Hale Reutershan, David L. Sloman, Michael D. Altman
  • PRMT5 inhibitors
    Patent number: 10947234
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: March 16, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, David J. Witter, Michael Hale Reutershan, Michael D. Altman, Paul Anthony Stupple
  • PRMT5 INHIBITORS
    Publication number: 20200361931
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 19, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, David J. Witter, Michael Hale Reutershan, Michael D. Altman, Paul Anthony Stupple
  • PRMT5 INHIBITORS
    Publication number: 20200354377
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.
    Type: Application
    Filed: November 5, 2018
    Publication date: November 12, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michelle R. Machacek, David J. Witter, Michael Hale Reutershan, David L. Sloman, Michael D. Altman
  • 2,6,7 substituted purines as HDM2 inhibitors
    Patent number: 9682978
    Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: June 20, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Liping Yang
  • Substituted pyrrolopyrimidines as HDM2 inhibitors
    Patent number: 9637493
    Abstract: The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: May 2, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher Dinsmore, Francesc Xavier Fradera Llinas, Amit Ashokro Kudale, Michelle Machacek, Michael Hale Reutershan, Christopher Francis Thompson, B. Wesley Trotter, Liping Yang, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll, Matthew E. Voss
  • 2,6,7,8 substituted purines as HDM2 inhibitors
    Patent number: 9540377
    Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: January 10, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Carolyn Michele Cammarano, Matthew P. Christopher, Christopher Dinsmore, Ronald J. Doll, Francesc Xavier Fradera Llinas, Chaomin Li, Michelle Machacek, Michelle Martinez, Latha G. Nair, Weidong Pan, Michael Hale Reutershan, Manami Shizuka, Dietrich P. Steinhuebel, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Yaolin Wang, Liping Yang, Stephane L. Bogen, Matthew E. Voss, Jagannath Panda, Anthappan Tony Kurissery
  • 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS
    Publication number: 20150368247
    Abstract: The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Liping Yang
  • 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS
    Publication number: 20150353553
    Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 10, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Carolyn Michele Cammarano, Matthew P. Christopher, Christopher Dinsmore, Ronald J. Doll, Francesc Xavier Fradera Llinas, Chaomin Li, Michelle Machacek, Michelle Martinez, Latha G. Nair, Weidong Pan, Michael Hale Reutershan, Manami Shizuka, Dietrich P. Steinhuebel, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Yaolin Wang, Liping Yang, Stephane L. Bogen, Matthew E. Voss, Jagannath Panda, Anthappan Tony Kurissery
  • SUBSTITUTED PYRROLOPYRIMIDINES AS HDM2 INHIBITORS
    Publication number: 20150329548
    Abstract: The present invention provides substituted pyrrolopyrimidines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Application
    Filed: December 18, 2013
    Publication date: November 19, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Christopher Dinsmore, Francesc Xavier Fradera Llinas, Amit Ashokro Kudale, Michelle Machacek, Michael Hale Reutershan, Christopher Francis Thompason, B. Wesley Trotter, Liping Yang, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll, Matthew E. Voss
  • Substituted imidazopyridines as HDM2 inhibitors
    Patent number: 8962611
    Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: February 24, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
  • SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS
    Publication number: 20140357618
    Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 4, 2014
    Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
  • Substituted imidazopyridines as HDM2 inhibitors
    Patent number: 8846657
    Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: September 30, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll
  • Substituted Imidazopyridines as HDM2 Inhibitors
    Publication number: 20140179680
    Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
    Type: Application
    Filed: December 18, 2013
    Publication date: June 26, 2014
    Inventors: Matthew P. Christopher, Francesc Xavier Fradera Llinas, Michelle Machacek, Michelle Martinez, Michael Hale Reutershan, Manami Shizuka, Binyuan Sun, Christopher Francis Thompson, B. Wesley Trotter, Matthew E. Voss, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll